CUE - キュ―・バイオファ―マ (Cue Biopharma Inc.) キュ―・バイオファ―マ

 CUEのチャート


 CUEの企業情報

symbol CUE
会社名 Cue Biopharma Inc (キュ―・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.   キュ―・バイオファ―マは米国のバイオ医薬品企業。がんや自己免疫疾患を治療するヒト免疫系の薬剤の開発に従事する。同社の薬剤候補にはT細胞を改善するCUE-100シリ―ズ、排出されたT細胞を活性化するCUE-200シリ―ズを含む。また、腫瘍の自己免疫疾患の適応症に対処するためのプラットフォ―ムを提供する。本社所在地はマサチュ―セッツ州ケンブリッジ。   Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.
本社所在地 21 Erie St. Cambridge MA 02139 USA
代表者氏名 Daniel R. Passeri ダニエル・R・パスジェリ
代表者役職名 President Chief Executive Officer
電話番号 +1 617-949-2680
設立年月日 41974
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.cuebiopharma.com
nasdaq_url https://www.nasdaq.com/symbol/cue
adr_tso
EBITDA EBITDA(百万ドル) -29.83774
終値(lastsale) 7.2262
時価総額(marketcap) 145487006.7692
時価総額 時価総額(百万ドル) 141.13420
売上高 売上高(百万ドル) 0.36300
企業価値(EV) 企業価値(EV)(百万ドル) 95.34820
当期純利益 当期純利益(百万ドル) -30.27878
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cue Biopharma Inc revenues increased from $0K to $363K. Net loss increased 91% to $14.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing va increase from $4.1M to $8.4M (expense) General and administrative - Balancing increase from $1.3M to $2.7M (expense).

 CUEのテクニカル分析


 CUEのニュース

   Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer  2021/06/10 12:38:36 Seeking Alpha
   Cue Biopharma doses the first patient in trial for CUE-101 in head and neck cancer  2021/06/10 12:36:54 Seeking Alpha
   Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC  2021/06/10 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.
   Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting  2021/06/03 00:00:00 BioSpace
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting , which is being held virtually from June 8-11, 2021.
   Cue Biopharma Consensus Indicates Potential 110.2% Upside  2021/06/01 15:37:04 DirectorsTalk
Cue Biopharma found using ticker (CUE) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 33 and 27 and has a mean target at 30. Now with the previous closing price of 14.27 this indicates there is a potential upside of 110.2%. The 50 day moving average now sits at 12.89 and the 200 day MA is 13.26. The company has a market capitalisation of $450m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release  2020/05/06 16:30:40 Zacks Investment Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1  2020/04/30 11:19:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) • Arvinas Inc (NASDAQ: ARVN ) • Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) • Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) • Capricor Therapeutics Inc (NASDAQ: CAPR )( reacted to data that showed a 100% survival rate in COVID-19 patients treated with its CAP-1002 cell therapy) • Cue Biopharma Inc (NASDAQ: CUE ) • DexCom, Inc. (NASDAQ: DXCM )(reacted to its quarterly results) • Erytech Pharma SA (NASDAQ: ERYP )(announced Fast Track Designation from the FDA for its cancer drug in pancreatic cancer) • GenMark Diagnostics, Inc (NASDAQ: GNMK ) • I-Mab ADR (NASDAQ: IMAB ) • Immunomedics, Inc. (NASDAQ: IMMU ) • Keros Therapeutics Inc (NASDAQ: KROS ) • Masimo Corporation (NASDAQ: MASI )(announced solid first-quarter results) • Mersana Therapeutics Inc (NASDAQ: MRSN ) • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) • Zynex Inc.
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release  2020/05/06 16:30:40 Zacks Investment Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1  2020/04/30 11:19:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) • Arvinas Inc (NASDAQ: ARVN ) • Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) • Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) • Capricor Therapeutics Inc (NASDAQ: CAPR )( reacted to data that showed a 100% survival rate in COVID-19 patients treated with its CAP-1002 cell therapy) • Cue Biopharma Inc (NASDAQ: CUE ) • DexCom, Inc. (NASDAQ: DXCM )(reacted to its quarterly results) • Erytech Pharma SA (NASDAQ: ERYP )(announced Fast Track Designation from the FDA for its cancer drug in pancreatic cancer) • GenMark Diagnostics, Inc (NASDAQ: GNMK ) • I-Mab ADR (NASDAQ: IMAB ) • Immunomedics, Inc. (NASDAQ: IMMU ) • Keros Therapeutics Inc (NASDAQ: KROS ) • Masimo Corporation (NASDAQ: MASI )(announced solid first-quarter results) • Mersana Therapeutics Inc (NASDAQ: MRSN ) • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) • Zynex Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―・バイオファ―マ CUE Cue Biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)